Skip to main content

Table 2 Comparison of clinicopathologic characteristics between patients with and without VER

From: Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study

Variables VER (n = 96) Non-VER (n = 125) P value
Gender(male) 79 (82.3%) 108 (86.4%) 0.515
Age (>= 65 years) 15 (15.6%) 24 (19.2%) 0.608
Hepatitis
 NBNC, n (%) 12 (12.5%) 18 (14.4%) 0.668
 HBV, n (%) 82 (85.4%) 106 (84.8%)
 HCV, n (%) 2 (2.1%) 1 (0.8%)
 NAFLD, n (%) 5 (5.2%) 6 (4.8%) 1
Cirrhosis (yes) 65 (67.7%) 84 (67.2%) 1
Resection type (major resection) 70 (72.9%) 73 (58.4%) 0.036
Lymph node dissection (yes) 24 (25.0%) 16 (12.8%) 0.031
Tumor number (multiple) 30 (31.3%) 29 (23.2%) 0.235
Tumor size (>= 5 cm) 66 (68.8%) 55 (44.0%) < 0.001
Tumor capsule (present) 52 (54.2%) 72 (57.6%) 0.709
Microvascular invasion (present) 77 (80.2%) 64 (51.2%) < 0.001
Macrovascular invasion (present) 38 (39.6%) 16 (12.8%) < 0.001
Satellite nodules (present) 48 (50.0%) 28 (22.4%) < 0.001
Edmondson-Steiner classification (III/IV) 21 (21.9%) 26 (20.8%) 0.978
RBC(>= 4 × 10^12/L) 10 (10.4%) 13 (10.4%) 1
Hb(< 120*g/L) 7 (7.3%) 9 (7.2%) 1
PLT(< 300 × 10^9/L) 86 (89.6%) 117 (93.6%) 0.404
Neutrophil count(>= 5 × 10^9/L) 63 (65.6%) 97 (77.6%) 0.068
Lymphocyte count(>= 1.5 × 10^9/L) 23 (24.0%) 32 (25.6%) 0.902
NLR(> = 1.6) 18 (18.8%) 30 (24.0%) 0.439
AST(>= 40 U/L) 49 (51.0%) 56 (44.8%) 0.432
PT(>= 13 s) 35 (36.5%) 40 (32.0%) 0.582
TB(>= 17.1 umol/L) 22 (22.9%) 34 (27.2%) 0.569
ALB(< 40 g/L) 33 (34.4%) 48 (38.4%) 0.635
GGT(>= 75 U/L) 54 (56.3%) 47 (37.6%) 0.009
ALP(>= 78 U/L) 77 (80.2%) 72 (57.6%) < 0.001
AFP(>= 20 ng/mL) 72 (75.0%) 72 (57.6%) 0.011
CEA(>= 5 ng/mL) 16 (16.7%) 18 (14.4%) 0.783
CA19-9(>= 25 U/mL) 63 (65.6%) 49 (39.2%) < 0.001
DCP(>= 200 mAU/mL) 41 (42.7%) 32 (25.6%) 0.011
Intraoperative blood loss(>= 200 mL) 60 (62.5%) 63 (50.4%) 0.097
Intraoperative blood transfusion (yes) 28 (29.2%) 42 (33.6%) 0.578
  1. HBV hepatitis B virus, HCV hepatitis C virus, NAFLD non-alcoholic fatty liver disease, RBC red blood cell, Hb hemoglobin, PLT platelet count, NLR neutrophils/lymphocytes ratio, AST aspartate aminotransferase, PT prothrombin time, TB total bilirubin, ALB albumin, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, DCP decarboxylic prothrombin